Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRT adjuvant immunotherapy for recurrence-risk hepatocellular carcinoma after radical resection
ChiCTR-OOC-16010023Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Disease-free survival and Immune index related to disease-free survival. Started Nov 2016; status: recruiting.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-OOC-16010023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OOC-16010023.